Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
Yonsei Medical Journal
;
: 695-698, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-33245
ABSTRACT
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Quinazolinas
/
Doenças do Colo Sigmoide
/
Fístula Intestinal
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Perfuração Intestinal
/
Antineoplásicos
Limite:
Idoso
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS